{"protocolSection": {"identificationModule": {"nctId": "NCT02589977", "orgStudyIdInfo": {"id": "141686"}, "organization": {"fullName": "Vanderbilt University Medical Center", "class": "OTHER"}, "briefTitle": "Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF", "officialTitle": "Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF", "acronym": "HFpEF-PRoF"}, "statusModule": {"statusVerifiedDate": "2021-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-11"}, "primaryCompletionDateStruct": {"date": "2020-01-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-01-21", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-08-24", "studyFirstSubmitQcDate": "2015-10-27", "studyFirstPostDateStruct": {"date": "2015-10-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-12-23", "resultsFirstSubmitQcDate": "2021-02-01", "resultsFirstPostDateStruct": {"date": "2021-02-02", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-02-01", "lastUpdatePostDateStruct": {"date": "2021-02-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Marvin W. Kronenberg, M.D.", "investigatorTitle": "Professor of Medicine and Radiology", "investigatorAffiliation": "Vanderbilt University Medical Center"}, "leadSponsor": {"name": "Marvin W. Kronenberg, M.D.", "class": "OTHER"}, "collaborators": [{"name": "Astellas Pharma US, Inc.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Unlike heart failure with reduced ejection fraction (HFrEF) where several medicines and devices have been demonstrated to reduce mortality, no such therapies have been identified in HFpEF. This may be in part due to incomplete understanding of the underlying mechanisms of HFpEF.\n\nRecently, impaired myocardial blood flow, reduced myocardial energy utilization, and increased myocardial fibrosis have been postulated to play important pathophysiologic roles in HFpEF. The investigators and others have demonstrated that HFrEF may be associated with altered myocardial energy utilization and \"energy starvation.\" However, there are limited data regarding \"energy starvation\" in HFpEF and the relationships between myocardial blood flow, energy utilization, and fibrosis in HFpEF are largely unknown. Therefore, the purposes of this study are to use non-invasive cardiac imaging techniques to describe cardiac structure, function, blood flow, energetics, and fibrosis, and the relationships between these in order to better understand underlying mechanisms in HFpEF.", "detailedDescription": "The investigators hypothesize that HFpEF is associated with reductions in myocardial blood flow and energy utilization and increased myocardial fibrosis as compared to age and gender matched hypertensive and healthy controls. The investigators will test their hypotheses by comparing measurements of myocardial blood flow, energy utilization, and fibrosis between three subject groups (HFpEF vs hypertension vs healthy). Myocardial blood flow will be quantitated from nitrogen (N)13-Ammonia positron emission tomography (PET) and gadolinium enhanced cardiac magnetic resonance (CMR) imaging, both at rest and stress following coronary vasodilation with regadenoson. Myocardial energy utilization will be quantified with 11C-acetate PET imaging and myocardial fibrosis will be assessed with gadolinium enhanced CMR and alterations in myocardial T1. Echocardiography will be utilized to quantify cardiac diastolic function.\n\nIt is anticipated that the results of this proposed study will provide a foundation that will inform future studies aimed at identifying novel preventive or therapeutic agents in HFpEF."}, "conditionsModule": {"conditions": ["Heart Failure, Diastolic", "Diastolic Heart Failure", "Hypertension"], "keywords": ["magnetic resonance imaging", "positron-emission tomography", "echocardiography", "myocardial blood flow", "energy metabolism"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "FACTORIAL", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 55, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "normal participants", "type": "OTHER", "description": "No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.", "interventionNames": ["Drug: regadenoson"]}, {"label": "hypertensive participants", "type": "OTHER", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.", "interventionNames": ["Drug: regadenoson"]}, {"label": "HFpEF patients", "type": "OTHER", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.", "interventionNames": ["Drug: regadenoson"]}], "interventions": [{"type": "DRUG", "name": "regadenoson", "description": "evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants", "armGroupLabels": ["HFpEF patients", "hypertensive participants", "normal participants"], "otherNames": ["positron emission tomography", "echocardiography", "cardiac magnetic resonance imaging"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Coronary Flow Reserve", "description": "Rest and regadenoson stress coronary flow reserve by ammonia PET. Coronary flow calculated at rest and again at stress with coronary flow reserve calculated as the ratio of stress to rest coronary flow.", "timeFrame": "Baseline study visit"}], "secondaryOutcomes": [{"measure": "Myocardial Perfusion Reserve by CMR in Each Study Group.", "description": "Myocardial perfusion reserve by CMR.", "timeFrame": "Baseline study visit."}, {"measure": "Extracellular Volume (ECV) by CMR in Each Study Group", "description": "Extracellular volume (ECV) by CMR.", "timeFrame": "Baseline study visit"}, {"measure": "Oxidative Metabolism (Kmono/Rate Pressure Product) by PET in Each Study Group.", "description": "Oxidative metabolism (Kmono/rate pressure product) by PET.", "timeFrame": "Baseline study visit"}, {"measure": "E/e' by Echo in Each Study Group.", "description": "E/e' by echo. E is the transmitral peak velocity in early diastole. e' is the early diastolic tissue Doppler velocity average between the septal and lateral mitral annulus. E/e' is the ratio of these two values.", "timeFrame": "Baseline study visit"}]}, "eligibilityModule": {"eligibilityCriteria": "ALL\n\nInclusion Criteria:\n\n* estimated glomerular filtration rate (eGFR) \\> 60 ml/min\n* preserved left ventricular ejection fraction (\\>= 50%) on echocardiography\n\nExclusion Criteria:\n\n* coronary artery disease\n* diabetes mellitus\n* contraindications to cardiac magnetic resonance imaging (CMR)\n* weight \\>350 lbs\n* inability to lie flat for imaging\n* anemia\n* contraindications to regadenoson or aminophylline\n\nHEALTHY\n\nInclusion criteria:\n\n* normal cardiac structure and function on echocardiography\n* BP \\< 140/90\n\nExclusion criteria:\n\n* known cardiovascular disease, cardiac risk factors or use of cardiac medications\n\nHYPERTENSIVE\n\nInclusion criteria:\n\n* history of BP \\>140/90\n* 1 or more antihypertensive medications\n* LV ejection fraction (LVEF) at least 50%\n* current BP \\< 160/90\n\nExclusion criteria:\n\n* known cardiovascular disease or risk factors aside from hypertension or use of cardiac medications\n\nHFpEF\n\nInclusion criteria:\n\n* physician-confirmed diagnosis of HF\n* symptomatic HF\n* LVEF at least 50%\n* elevated LV filling pressure by catheterization, echocardiographic criteria or B-type-natriuretic peptide \\> 100\n* current BP \\< 160/90\n\nExclusion criteria:\n\n* prior history of LVEF below 50%\n* acute decompensated HF\n* moderate or greater valvular disease\n* significant cardiac arrhythmias\n* pericardial disease\n* congenital heart disease\n* primary pulmonary hypertension", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "50 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Marvin W Kronenberg, MD", "affiliation": "Vanderbilt University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Vanderbilt University Medical Center", "city": "Nashville", "state": "Tennessee", "zip": "37232", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}]}, "referencesModule": {"references": [{"pmid": "24331202", "type": "RESULT", "citation": "Bell SP, Adkisson DW, Ooi H, Sawyer DB, Lawson MA, Kronenberg MW. Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy. J Card Fail. 2013 Dec;19(12):802-10. doi: 10.1016/j.cardfail.2013.10.010. Epub 2013 Oct 29."}, {"pmid": "23671819", "type": "RESULT", "citation": "Gupta DK, Shah AM, Castagno D, Takeuchi M, Loehr LR, Fox ER, Butler KR, Mosley TH, Kitzman DW, Solomon SD. Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study. JACC Heart Fail. 2013 Apr;1(2):156-63. doi: 10.1016/j.jchf.2013.01.003."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Normal Participants", "description": "No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "FG001", "title": "Hypertensive Participants", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "FG002", "title": "HFpEF Patients", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "20"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "These are the people who attended baseline visit.", "groups": [{"id": "BG000", "title": "Normal Participants", "description": "No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "BG001", "title": "Hypertensive Participants", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "BG002", "title": "HFpEF Patients", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "40"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57", "lowerLimit": "54", "upperLimit": "62"}, {"groupId": "BG001", "value": "58", "lowerLimit": "54", "upperLimit": "65"}, {"groupId": "BG002", "value": "69", "lowerLimit": "62", "upperLimit": "73"}, {"groupId": "BG003", "value": "58", "lowerLimit": "55", "upperLimit": "67"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "24"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "16"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "38"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "40"}]}]}]}, {"title": "Hypertension", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "23"}]}]}]}, {"title": "Diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "3"}]}]}]}, {"title": "BMI", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.7", "lowerLimit": "22.6", "upperLimit": "28.7"}, {"groupId": "BG001", "value": "30.1", "lowerLimit": "27.8", "upperLimit": "35.7"}, {"groupId": "BG002", "value": "34.2", "lowerLimit": "29.9", "upperLimit": "37.8"}, {"groupId": "BG003", "value": "29.7", "lowerLimit": "25.6", "upperLimit": "33.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Coronary Flow Reserve", "description": "Rest and regadenoson stress coronary flow reserve by ammonia PET. Coronary flow calculated at rest and again at stress with coronary flow reserve calculated as the ratio of stress to rest coronary flow.", "populationDescription": "Incomplete data for 18 because of either inability to complete scan OR scan quality not adequate for analysis.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "ratio", "timeFrame": "Baseline study visit", "groups": [{"id": "OG000", "title": "Normal Participants", "description": "No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "OG001", "title": "Hypertensive Participants", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "OG002", "title": "HFpEF Patients", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.64", "lowerLimit": "2.34", "upperLimit": "2.85"}, {"groupId": "OG001", "value": "2.65", "lowerLimit": "2.56", "upperLimit": "3.11"}, {"groupId": "OG002", "value": "2.06", "lowerLimit": "1.96", "upperLimit": "2.26"}]}]}]}, {"type": "SECONDARY", "title": "Myocardial Perfusion Reserve by CMR in Each Study Group.", "description": "Myocardial perfusion reserve by CMR.", "populationDescription": "Incomplete data for 10 because of either inability to complete scan OR scan quality not adequate for analysis.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "ratio", "timeFrame": "Baseline study visit.", "groups": [{"id": "OG000", "title": "Normal Participants", "description": "No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "OG001", "title": "Hypertensive Participants", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "OG002", "title": "HFpEF Patients", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.19", "lowerLimit": "1.81", "upperLimit": "2.64"}, {"groupId": "OG001", "value": "1.74", "lowerLimit": "1.44", "upperLimit": "2.59"}, {"groupId": "OG002", "value": "1.29", "lowerLimit": "1.11", "upperLimit": "1.32"}]}]}]}, {"type": "SECONDARY", "title": "Extracellular Volume (ECV) by CMR in Each Study Group", "description": "Extracellular volume (ECV) by CMR.", "populationDescription": "Incomplete data for 9 because of either inability to complete scan OR scan quality not adequate for analysis.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percent ECV", "timeFrame": "Baseline study visit", "groups": [{"id": "OG000", "title": "Normal Participants", "description": "No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "OG001", "title": "Hypertensive Participants", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "OG002", "title": "HFpEF Patients", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31.9", "lowerLimit": "28.5", "upperLimit": "34.2"}, {"groupId": "OG001", "value": "29.2", "lowerLimit": "27.4", "upperLimit": "33.1"}, {"groupId": "OG002", "value": "30.9", "lowerLimit": "29.4", "upperLimit": "32.8"}]}]}]}, {"type": "SECONDARY", "title": "Oxidative Metabolism (Kmono/Rate Pressure Product) by PET in Each Study Group.", "description": "Oxidative metabolism (Kmono/rate pressure product) by PET.", "populationDescription": "Incomplete data for 4 because of either inability to complete scan OR scan quality not adequate for analysis.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "min-1/(beats/min x mmhg)", "timeFrame": "Baseline study visit", "groups": [{"id": "OG000", "title": "Normal Participants", "description": "No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "OG001", "title": "Hypertensive Participants", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "OG002", "title": "HFpEF Patients", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "lowerLimit": "0.10", "upperLimit": "0.13"}, {"groupId": "OG001", "value": "0.09", "lowerLimit": "0.07", "upperLimit": "0.11"}, {"groupId": "OG002", "value": "0.09", "lowerLimit": "0.09", "upperLimit": "0.10"}]}]}]}, {"type": "SECONDARY", "title": "E/e' by Echo in Each Study Group.", "description": "E/e' by echo. E is the transmitral peak velocity in early diastole. e' is the early diastolic tissue Doppler velocity average between the septal and lateral mitral annulus. E/e' is the ratio of these two values.", "populationDescription": "We were able to collect data on all participants who completed the study.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "ratio", "timeFrame": "Baseline study visit", "groups": [{"id": "OG000", "title": "Normal Participants", "description": "No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "OG001", "title": "Hypertensive Participants", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}, {"id": "OG002", "title": "HFpEF Patients", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.2", "lowerLimit": "6.4", "upperLimit": "9.0"}, {"groupId": "OG001", "value": "8.2", "lowerLimit": "7.2", "upperLimit": "9.4"}, {"groupId": "OG002", "value": "13.0", "lowerLimit": "10.2", "upperLimit": "18.9"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "This is a cross sectional study. Subjects were followed for adverse events between screening/enrollment to one day following completion of the cardiac imaging study visit. Because this was not a longitudinal study with serial measurements of the end points the time between enrollment and cross sectional cardiac imaging study visit was variable for each subject in accordance with the study protocol. All subjects completed study procedures within thirteen months of enrollment.", "eventGroups": [{"id": "EG000", "title": "Normal Participants", "description": "No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 0, "otherNumAtRisk": 23}, {"id": "EG001", "title": "Hypertensive Participants", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants", "deathsNumAffected": 0, "deathsNumAtRisk": 20, "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 0, "otherNumAtRisk": 20}, {"id": "EG002", "title": "HFpEF Patients", "description": "No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \\>60.\n\nStudies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.\n\nregadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 0, "otherNumAtRisk": 12}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Marvin Kronenberg, MD", "organization": "Vanderbilt University Medical Center", "email": "marvin.w.kronenberg@vumc.org", "phone": "615-322-2318"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2019-04-10", "uploadDate": "2020-12-15T10:52", "filename": "Prot_SAP_000.pdf", "size": 775898}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000054144", "term": "Heart Failure, Diastolic"}], "ancestors": [{"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006331", "term": "Heart Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M8485", "name": "Fibrosis", "relevance": "LOW"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "asFound": "Heart Failure, Diastolic", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000430916", "term": "Regadenoson"}], "ancestors": [{"id": "D000058908", "term": "Adenosine A2 Receptor Agonists"}, {"id": "D000058906", "term": "Purinergic P1 Receptor Agonists"}, {"id": "D000058913", "term": "Purinergic Agonists"}, {"id": "D000058905", "term": "Purinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M227440", "name": "Regadenoson", "asFound": "Solution for infusion", "relevance": "HIGH"}, {"id": "M3595", "name": "Adenosine", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Analg", "name": "Analgesics"}]}}, "hasResults": true}